Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WI › Hayward › NPI 1912992827
Hospital

Medical Services, INC

Medical Services, INC was paid $14.75M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 16% of everything it billed.

33Billing provider infoMEDICAL SERVICES, INC
HAYWARD, WI 54843
33aNPI1912992827assigned 09/16/2005
33bProvider typeCritical Access Hospital
28Total paid$14.75M
24GClaims283,679
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Critical Access Hospital providers in Wisconsin

Rank by total paid#2 of 48
Median peer was paid$4.30M
This provider vs. median3.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201830,506$1.62M
201932,866$1.67M
202037,061$1.86M
202146,800$1.98M
202245,120$2.18M
202350,182$2.85M
2024incomplete41,144$2.59M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
96361 Intravenous infusion, hydration; each additional hour 16% 4,955 3,810 $2.35M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 11% 12,733 10,872 $1.63M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 10% 9,291 7,715 $1.48M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 8.6% 6,308 5,201 $1.27M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 7.6% 10,165 8,701 $1.12M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 6.6% 3,788 2,821 $975K
70450 Computed tomography, head or brain; without contrast material 3.8% 2,074 1,843 $566K
74177 Computed tomography, abdomen and pelvis; with contrast material 3.5% 1,857 1,683 $514K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 3.4% 5,376 4,682 $499K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 2.3% 1,281 1,106 $341K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.3% 10,328 3,803 $333K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 2.1% 2,546 2,236 $302K
163 more codes
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.0% 1,850 $288K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 1.9% 2,202 $280K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 1.8% 692 $268K
99203 Doctor's office visit, new patient (routine) 1.3% 1,807 $196K
87631 <1% 1,340 $134K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 825 $131K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,232 $112K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 5,623 $109K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 5,479 $108K
80053 Comprehensive metabolic panel <1% 10,926 $99K
71275 Computed tomographic angiography, chest, with contrast material <1% 334 $90K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 2,073 $81K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 976 $77K
99204 Doctor's office visit, new patient (more involved) <1% 980 $76K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 13,898 $74K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 1,946 $73K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 2,039 $70K
96367 <1% 403 $67K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 2,332 $65K
97161 <1% 1,491 $65K
87632 <1% 399 $64K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 181 $45K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 2,898 $42K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 6,989 $37K
80306 <1% 2,295 $33K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 733 $32K
84484 <1% 4,725 $31K
72125 Computed tomography, cervical spine; without contrast material <1% 304 $29K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 114 $27K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 1,056 $25K
84443 Thyroid stimulating hormone (TSH) <1% 2,135 $23K
80048 Basic metabolic panel (calcium, ionized) <1% 2,762 $22K
G0378 Hospital observation service, per hour <1% 406 $22K
83605 <1% 3,138 $21K
84703 <1% 2,635 $20K
83735 <1% 4,726 $19K
81001 <1% 4,687 $19K
86140 <1% 5,560 $18K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 162 $16K
83880 <1% 1,129 $15K
82803 <1% 1,112 $15K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 465 $15K
83690 <1% 2,872 $15K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 4,800 $14K
77067 Screening mammography, bilateral, including computer-aided detection <1% 271 $13K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 617 $12K
77063 Screening digital breast tomosynthesis, bilateral <1% 266 $12K
71046 Radiologic examination, chest; 2 views <1% 1,220 $11K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 151 $11K
87086 Culture, bacterial; quantitative colony count, urine <1% 1,894 $11K
85379 <1% 1,540 $9K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 180 $9K
84145 <1% 731 $9K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 603 $9K
87040 <1% 1,775 $8K
87070 <1% 579 $8K
80320 <1% 1,915 $8K
81003 <1% 2,642 $8K
87486 <1% 236 $8K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 44 $7K
87077 <1% 1,571 $7K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 2,443 $7K
87581 <1% 236 $7K
87186 <1% 1,321 $6K
20610 <1% 39 $6K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 223 $6K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 223 $6K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 409 $6K
85610 <1% 2,194 $6K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 6,914 $5K
76801 <1% 30 $5K
82962 <1% 2,231 $5K
71045 Radiologic examination, chest; single view <1% 4,810 $4K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 15 $4K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 60 $3K
81025 <1% 324 $3K
M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring <1% 15 $3K
87634 <1% 37 $3K
73630 <1% 335 $3K
86618 <1% 214 $2K
87081 <1% 108 $2K
81002 <1% 284 $2K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 13 $2K
90686 <1% 73 $2K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 13 $2K
73562 <1% 221 $2K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 60 $2K
73030 <1% 123 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 151 $1K
36415 Collection of venous blood by venipuncture <1% 9,929 $1K
73610 <1% 83 $1K
71250 <1% 16 $1K
96375 Therapeutic injection; each additional sequential IV push <1% 4,232 $1K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 3,331 $1K
85027 <1% 208 $990.80
80329 <1% 989 $754.16
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 10,611 $671.46
97162 <1% 21 $667.71
87420 <1% 35 $509.36
74018 <1% 26 $446.12
J7030 Infusion, normal saline solution , 1000 cc <1% 3,712 $444.01
83036 Hemoglobin; glycosylated (A1C) <1% 45 $437.16
85730 <1% 113 $378.81
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 284 $350.78
96376 <1% 985 $336.30
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 3,609 $307.44
86780 <1% 40 $292.67
73110 <1% 133 $260.41
84460 <1% 78 $252.08
84075 <1% 78 $246.10
82040 <1% 79 $229.95
90461 <1% 15 $218.56
86850 <1% 67 $212.46
87205 <1% 73 $198.45
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 910 $196.63
82247 <1% 78 $195.04
82800 <1% 25 $182.44
84155 <1% 78 $174.34
J7120 Ringers lactate infusion, up to 1000 cc <1% 1,636 $167.89
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 2,147 $155.67
86900 <1% 78 $146.55
86901 <1% 78 $145.89
73502 <1% 32 $134.82
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 13 $108.00
87210 <1% 15 $104.00
85018 <1% 30 $90.35
73130 <1% 16 $80.65
J2704 Injection, propofol, 10 mg <1% 1,731 $74.71
94761 <1% 528 $73.79
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 3,376 $65.78
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 66 $60.66
J3490 Unclassified drugs <1% 460 $57.75
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 75 $51.46
J2270 Injection, morphine sulfate, up to 10 mg <1% 119 $48.92
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 383 $46.68
85651 <1% 12 $28.98
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 125 $20.92
80050 General health panel <1% 13 $14.88
A9576 Injection, gadoteridol, (prohance multipack), per ml <1% 17 $10.61
J3010 Injection, fentanyl citrate, 0.1 mg <1% 737 $9.60
J2060 Injection, lorazepam, 2 mg <1% 417 $9.06
J1170 Injection, hydromorphone, up to 4 mg <1% 797 $8.71
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 462 $6.51
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 57 $6.05
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 13 $5.77
A9270 Non-covered item or service <1% 4,355 $3.52
C9113 Injection, pantoprazole sodium, per vial <1% 312 $1.11
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 20 $0.02
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) 0% 294 $0.00
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg 0% 12 $0.00
J1200 Injection, diphenhydramine hcl, up to 50 mg 0% 75 $0.00
J3475 Injection, magnesium sulfate, per 500 mg 0% 46 $0.00
E0445 Oximeter device for measuring blood oxygen levels non-invasively 0% 49 $0.00
J0780 Injection, prochlorperazine, up to 10 mg 0% 17 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 21 $0.00
J1815 Injection, insulin, per 5 units 0% 54 $0.00
J0131 Injection, acetaminophen, not otherwise specified,10 mg 0% 16 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 15 $0.00
94760 0% 17 $0.00
J0690 Injection, cefazolin sodium, 500 mg 0% 123 $0.00
G0379 Direct admission of patient for hospital observation care 0% 15 $0.00
J3480 Injection, potassium chloride, per 2 meq 0% 114 $0.00
J7512 Prednisone, immediate release or delayed release, oral, 1 mg 0% 21 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBEIRL, LUKE (CEO)